Safety and pharmacokinetics of BAY 1817080, a P2X3 receptor antagonist, in healthy subjects: Results from a double-blind, randomised study

被引：0
|
作者：
Friedrich, Christian [1 ]
Francke, Klaus [1 ]
Gashaw, Isabella [1 ]
Scheerans, Christian [1 ]
Klein, Stefan [1 ]
Fels, Lueder [1 ]
Smith, Jaclyn [2 ,3 ]
Hummel, Thomas [4 ]
Morice, Alyn [5 ]
机构：
[1] Bayer AG, Leverkusen, Germany
[2] Univ Manchester, Immun & Resp Med, Manchester, Lancs, England
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[4] Tech Univ Dresden, Dept Otorhinolaryngol, Smell & Taste Clin, Dresden, Germany
[5] Univ Hull, Resp Res Grp, Hull York Med Sch, Kingston Upon Hull, N Humberside, England
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2021年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P132
引用
收藏
页码：1614 / 1616
页数：3
相关论文
共 50 条
  • [1] Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study
    Friedrich, Christian
    Francke, Klaus
    Gashaw, Isabella
    Scheerans, Christian
    Klein, Stefan
    Fels, Lueder
    Smith, Jaclyn A.
    Hummel, Thomas
    Morice, Alyn
    CLINICAL PHARMACOKINETICS, 2022, 61 (08) : 1143 - 1156
  • [2] Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study
    Christian Friedrich
    Klaus Francke
    Isabella Gashaw
    Christian Scheerans
    Stefan Klein
    Lueder Fels
    Jaclyn A. Smith
    Thomas Hummel
    Alyn Morice
    Clinical Pharmacokinetics, 2022, 61 : 1143 - 1156
  • [3] First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
    Klein, Stefan
    Gashaw, Isabella
    Baumann, Sybille
    Chang, Xinying
    Hummel, Thomas
    Thuss, Uwe
    Friedrich, Christian
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (10) : 4552 - 4564
  • [4] Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
    Yuru Fan
    Xuan Zhang
    Qin Zhang
    Liang Zheng
    Renpeng Zhou
    Cheng Sun
    Xihan Wang
    Ke Song
    Zhusheng He
    Honghui Wang
    Qian Zhang
    Wei Hu
    Clinical Pharmacokinetics, 2024, 63 : 293 - 302
  • [5] Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
    Fan, Yuru
    Zhang, Xuan
    Zhang, Qin
    Zheng, Liang
    Zhou, Renpeng
    Sun, Cheng
    Wang, Xihan
    Song, Ke
    He, Zhusheng
    Wang, Honghui
    Zhang, Qian
    Hu, Wei
    CLINICAL PHARMACOKINETICS, 2024, 63 (03) : 293 - 302
  • [6] Safety and Efficacy of BAY 1817080, a P2X3 Receptor Antagonist, in Patients with Refractory Chronic Cough (RCC)
    Morice, A. H.
    Smith, J.
    McGarvey, L.
    Birring, S.
    Parker, S. M.
    Turner, A.
    Gashaw, I.
    Fels, L.
    Klein, S.
    Francke, K.
    Friedrich, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [7] Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study
    Morice, Alyn
    Smith, Jaclyn A.
    McGarvey, Lorcan
    Birring, Surinder S.
    Parker, Sean M.
    Turner, Alice
    Hummel, Thomas
    Gashaw, Isabella
    Fels, Lueder
    Klein, Stefan
    Francke, Klaus
    Friedrich, Christian
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58 (05)
  • [8] P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
    Abdulqawi, Rayid
    Dockry, Rachel
    Holt, Kimberley
    Layton, Gary
    McCarthy, Bruce G.
    Ford, Anthony P.
    Smith, Jaclyn A.
    LANCET, 2015, 385 (9974): : 1198 - 1205
  • [9] Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist
    Nussbaum, Jesse C.
    Hussain, Azher
    Min, K. Chris
    Marbury, Thomas C.
    Lasseter, Kenneth
    Stoch, S. Aubrey
    Iwamoto, Marian
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (11): : 1435 - 1444
  • [10] BLU-5937 a Highly Selective P2X3 Homotrimeric Receptor Antagonist with Improved Taste Safety Profile in Healthy Subjects
    Garceau, D.
    Chauret, N.
    Harvey, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345